JP2018516877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516877A5 JP2018516877A5 JP2017556212A JP2017556212A JP2018516877A5 JP 2018516877 A5 JP2018516877 A5 JP 2018516877A5 JP 2017556212 A JP2017556212 A JP 2017556212A JP 2017556212 A JP2017556212 A JP 2017556212A JP 2018516877 A5 JP2018516877 A5 JP 2018516877A5
- Authority
- JP
- Japan
- Prior art keywords
- igf
- antibody
- antigen
- binding fragment
- determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- 239000012472 biological sample Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 210000004881 tumor cell Anatomy 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 7
- 230000037361 pathway Effects 0.000 claims 7
- 229940125644 antibody drug Drugs 0.000 claims 6
- 231100000590 oncogenic Toxicity 0.000 claims 6
- 230000002246 oncogenic effect Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020088582A JP6977105B2 (ja) | 2015-04-27 | 2020-05-21 | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305642 | 2015-04-27 | ||
| EP15305642.9 | 2015-04-27 | ||
| PCT/EP2016/059338 WO2016174053A1 (en) | 2015-04-27 | 2016-04-27 | Igf-1r antibody and its use for the diagnosis of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020088582A Division JP6977105B2 (ja) | 2015-04-27 | 2020-05-21 | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516877A JP2018516877A (ja) | 2018-06-28 |
| JP2018516877A5 true JP2018516877A5 (enExample) | 2019-06-06 |
Family
ID=53039833
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556212A Pending JP2018516877A (ja) | 2015-04-27 | 2016-04-27 | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 |
| JP2020088582A Expired - Fee Related JP6977105B2 (ja) | 2015-04-27 | 2020-05-21 | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020088582A Expired - Fee Related JP6977105B2 (ja) | 2015-04-27 | 2020-05-21 | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10753937B2 (enExample) |
| EP (1) | EP3288979B1 (enExample) |
| JP (2) | JP2018516877A (enExample) |
| KR (1) | KR102350251B1 (enExample) |
| CN (1) | CN107690439B (enExample) |
| AR (1) | AR104413A1 (enExample) |
| AU (1) | AU2016254661B2 (enExample) |
| BR (1) | BR112017022974A2 (enExample) |
| CA (1) | CA2983548C (enExample) |
| CY (1) | CY1124070T1 (enExample) |
| DK (1) | DK3288979T3 (enExample) |
| ES (1) | ES2875753T3 (enExample) |
| HR (1) | HRP20210858T1 (enExample) |
| HU (1) | HUE054402T2 (enExample) |
| IL (1) | IL255273B (enExample) |
| LT (1) | LT3288979T (enExample) |
| MA (1) | MA41987B1 (enExample) |
| MX (1) | MX382055B (enExample) |
| MY (1) | MY187583A (enExample) |
| NZ (1) | NZ736924A (enExample) |
| PL (1) | PL3288979T3 (enExample) |
| PT (1) | PT3288979T (enExample) |
| RS (1) | RS62024B1 (enExample) |
| RU (1) | RU2706967C2 (enExample) |
| SA (1) | SA517390248B1 (enExample) |
| SI (1) | SI3288979T1 (enExample) |
| TN (1) | TN2017000451A1 (enExample) |
| TW (1) | TWI740824B (enExample) |
| UA (1) | UA121047C2 (enExample) |
| WO (1) | WO2016174053A1 (enExample) |
| ZA (1) | ZA201707249B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017072196A1 (en) * | 2015-10-26 | 2017-05-04 | Pierre Fabre Medicament | Composition for the treatment of igf-1r expressing cancer |
| WO2018217459A2 (en) * | 2017-05-23 | 2018-11-29 | Academia Sinica | Conditional internalization of pegylated agents by pretargeting bi-specific peg-binding antibodies for diagnosis and therapy |
| RU2713795C1 (ru) * | 2019-06-13 | 2020-02-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования возможности озлокачествления опухоли яичника у женщин репродуктивного возраста |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0709843A2 (pt) * | 2006-03-28 | 2011-07-26 | Biogen Idec Inc | anticorpos de anti-igf-1r e usos dos mesmos |
| CN101415728A (zh) * | 2006-03-28 | 2009-04-22 | 比奥根艾迪克Ma公司 | 抗-igf-1r抗体及其用途 |
| FR2906533B1 (fr) * | 2006-09-28 | 2013-02-22 | Pf Medicament | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
| AR064464A1 (es) * | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
| US20130084243A1 (en) * | 2010-01-27 | 2013-04-04 | Liliane Goetsch | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
| EP2190480A4 (en) * | 2007-08-28 | 2013-01-23 | Biogen Idec Inc | ANTI-IGR-1R ANTIBODIES AND ITS USES |
| EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
-
2016
- 2016-04-26 AR ARP160101176A patent/AR104413A1/es not_active Application Discontinuation
- 2016-04-26 TW TW105112967A patent/TWI740824B/zh not_active IP Right Cessation
- 2016-04-27 CN CN201680024231.3A patent/CN107690439B/zh not_active Expired - Fee Related
- 2016-04-27 DK DK16722812.1T patent/DK3288979T3/da active
- 2016-04-27 US US15/569,566 patent/US10753937B2/en not_active Expired - Fee Related
- 2016-04-27 MY MYPI2017704030A patent/MY187583A/en unknown
- 2016-04-27 BR BR112017022974-9A patent/BR112017022974A2/pt not_active IP Right Cessation
- 2016-04-27 KR KR1020177032201A patent/KR102350251B1/ko not_active Expired - Fee Related
- 2016-04-27 NZ NZ736924A patent/NZ736924A/en not_active IP Right Cessation
- 2016-04-27 AU AU2016254661A patent/AU2016254661B2/en not_active Ceased
- 2016-04-27 HR HRP20210858TT patent/HRP20210858T1/hr unknown
- 2016-04-27 PT PT167228121T patent/PT3288979T/pt unknown
- 2016-04-27 MA MA41987A patent/MA41987B1/fr unknown
- 2016-04-27 CA CA2983548A patent/CA2983548C/en active Active
- 2016-04-27 JP JP2017556212A patent/JP2018516877A/ja active Pending
- 2016-04-27 EP EP16722812.1A patent/EP3288979B1/en active Active
- 2016-04-27 HU HUE16722812A patent/HUE054402T2/hu unknown
- 2016-04-27 LT LTEP16722812.1T patent/LT3288979T/lt unknown
- 2016-04-27 RS RS20210687A patent/RS62024B1/sr unknown
- 2016-04-27 MX MX2017013808A patent/MX382055B/es unknown
- 2016-04-27 PL PL16722812T patent/PL3288979T3/pl unknown
- 2016-04-27 RU RU2017140467A patent/RU2706967C2/ru active
- 2016-04-27 WO PCT/EP2016/059338 patent/WO2016174053A1/en not_active Ceased
- 2016-04-27 SI SI201631234T patent/SI3288979T1/sl unknown
- 2016-04-27 ES ES16722812T patent/ES2875753T3/es active Active
- 2016-04-27 UA UAA201711486A patent/UA121047C2/uk unknown
- 2016-04-27 TN TNP/2017/000451A patent/TN2017000451A1/en unknown
-
2017
- 2017-10-25 ZA ZA2017/07249A patent/ZA201707249B/en unknown
- 2017-10-26 SA SA517390248A patent/SA517390248B1/ar unknown
- 2017-10-26 IL IL255273A patent/IL255273B/en active IP Right Grant
-
2020
- 2020-05-21 JP JP2020088582A patent/JP6977105B2/ja not_active Expired - Fee Related
- 2020-06-30 US US16/917,376 patent/US20210018508A1/en not_active Abandoned
-
2021
- 2021-04-26 CY CY20211100357T patent/CY1124070T1/el unknown